Intuitive Surgical's Stock Soars 26.85% in a Week, Boosted by Quarterly Results
Intuitive Surgical experienced a remarkably positive week on the American markets, with a spectacular rise far exceeding that of the Nasdaq. Following the announcement of quarterly results that exceeded expectations, the stock of the robotic medical equipment giant continued its bullish trend, closing at $551.30 on October 23. This performance reflects a surge of optimism among investors about the company’s growth trajectory.
Significant Surge in Stock Value
The stock settled at $551.30 at the close of October 23, up 4.61% from the previous session. This latest jump comes after a week of stock market euphoria for the da Vinci surgical robots specialist, accumulating a rise of 26.85% since the beginning of the week. In comparison, the Nasdaq rose by 0.88% on October 23 and has gained 26.15% over the past year, signaling a significant outperformance by Intuitive Surgical. The trading volume for the day was established at 4.01 million shares, representing 1.12% of the market capitalization, indicating a normal intensity reflecting keen interest in the stock. Over a longer horizon, the stock records an annual performance of 7.55%, suggesting a bullish momentum that has accelerated in recent days.
Revitalization Driven by Strong Quarterly Results
This stock market revitalization originates from the third-quarter 2025 results announced on October 22 after market close. Intuitive Surgical reported revenue of $2.51 billion, surpassing the estimates of $2.40 billion and demonstrating the robustness of its business model. Even more impressive, the adjusted earnings per share stood at $2.40 compared to the $1.98 expected by the consensus. The company’s trajectory is thus strengthened: it anticipates a growth in procedures for its da Vinci system of 17% to 17.5% for the year 2025, thus improving its previous forecasts which were between 15.5% and 17%. Additionally, the company has revised downward its exposure to tariff impacts, moving from an estimated impact of 1% of revenue to 0.7%, representing a welcome improvement in the context of trade tensions with China. Concurrently, HSBC revised its price target upwards on October 23, raising it from $595 to $644, thus validating the positive momentum.
